Moomoo AI 已提取核心訊息
Agilent Technologies, a leading company in the diagnostics and genomics sector, has announced a significant reorganization of its business segments. The company has moved its Cell Analysis Division from the Life Sciences and Applied Markets Group (LSAG) to the Diagnostics and Genomics Group (DGG) as of December 20, 2023. This strategic move aims to enhance growth opportunities for both segments. Despite the reorganization, Agilent will maintain its three business segments: LSAG, DGG, and Agilent CrossLab, all of which will continue to be reportable segments. The company will present its financial statements reflecting the new structure starting with the quarter ending January 31, 2024, with prior periods being recast to align with the changes. This information was disclosed in a Current Report on Form 8-K filed with the SEC, which includes selected segment information and is not intended for filing purposes under Section 18 of the Securities Exchange Act of 1934, nor is it to be incorporated by reference into any registration statement or other document.
Agilent Technologies, a leading company in the diagnostics and genomics sector, has announced a significant reorganization of its business segments. The company has moved its Cell Analysis Division from the Life Sciences and Applied Markets Group (LSAG) to the Diagnostics and Genomics Group (DGG) as of December 20, 2023. This strategic move aims to enhance growth opportunities for both segments. Despite the reorganization, Agilent will maintain its three business segments: LSAG, DGG, and Agilent CrossLab, all of which will continue to be reportable segments. The company will present its financial statements reflecting the new structure starting with the quarter ending January 31, 2024, with prior periods being recast to align with the changes. This information was disclosed in a Current Report on Form 8-K filed with the SEC, which includes selected segment information and is not intended for filing purposes under Section 18 of the Securities Exchange Act of 1934, nor is it to be incorporated by reference into any registration statement or other document.
診斷和基因組學領域的領先公司安捷倫科技宣佈對其業務部門進行重大重組。自2023年12月20日起，該公司已將其細胞分析部門從生命科學與應用市場集團（LSAG）移至診斷和基因組學組（DGG）。這一戰略舉措旨在增加這兩個細分市場的增長機會。儘管進行了重組，但安捷倫仍將維持其三個業務領域：LSAG、DGG和安捷倫CrossLab，所有這些業務部門都將繼續是可申報的細分市場。從截至2024年1月31日的季度開始，該公司將提交反映新結構的財務報表，並對前幾期進行了重組以適應變化。這些信息是在向美國證券交易委員會提交的表格8-K的最新報告中披露的，該報告包括選定的分部信息，不用於1934年《證券交易法》第18條規定的申報目的，也不得以引用方式納入任何註冊聲明或其他文件中。
診斷和基因組學領域的領先公司安捷倫科技宣佈對其業務部門進行重大重組。自2023年12月20日起，該公司已將其細胞分析部門從生命科學與應用市場集團（LSAG）移至診斷和基因組學組（DGG）。這一戰略舉措旨在增加這兩個細分市場的增長機會。儘管進行了重組，但安捷倫仍將維持其三個業務領域：LSAG、DGG和安捷倫CrossLab，所有這些業務部門都將繼續是可申報的細分市場。從截至2024年1月31日的季度開始，該公司將提交反映新結構的財務報表，並對前幾期進行了重組以適應變化。這些信息是在向美國證券交易委員會提交的表格8-K的最新報告中披露的，該報告包括選定的分部信息，不用於1934年《證券交易法》第18條規定的申報目的，也不得以引用方式納入任何註冊聲明或其他文件中。
有用
沒用